OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor
Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT ® .TB tests sold in the third quarter exceeded one million tests for the first time Significant improvement in GAAP net loss; first quarter of positive non-GAAP adjusted EBITDA OXFORD, United Kingdom
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018 .
Oxford Immunotec's T-SPOT®.TB Tuberculosis and Accutix™ Tick-Borne Disease Testing Services are Part of Quest Diagnostics' Portfolio of Innovative Infectious Disease Diagnostics Tests, Broadening Access in the United States SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass., Nov.
Acquisition to broaden access to tuberculosis (TB) IGRA blood testing in the United States SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass. , Sept. 25, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Oxford Immunotec
Second quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United States Gross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basis Launch of transformative T-Cell Select™ product to enable full automation of T-SPOT
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the new CE-marked T-Cell Select kit in Europe and select ROW countries.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018 . Dr.
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent
Harnessing the power of T cell measurement
